Diane Hanna (“Hanna”) was promoted to vice president, medical affairs in March 2024; she joined Arcutis in 2021 and has held roles of increasing responsibility within the organization, initially serving as principal medical science liaison and shortly thereafter being promoted to executive medical director, where she was responsible for shaping and executing medical strategy. Prior to Arcutis, Dr Hanna served as senior medical science liaison, most recently at Sanofi Genzyme (dupilumab) and Celgene (apremilast). Dr Hanna’s focus and area of expertise is pre-FDA approval where she launched more than a dozen therapies in the topical, oral, and biologic space over her decades of experience. Throughout this entire time, Dr Hanna has continued to take care of dermatology patients—she is the director of clinical research at Modern Dermatology, where she specializes in the care of patients with atopic dermatitis. Dr Hanna has held numerous leadership positions, including Society of Aesthetic Injectors (SAI) board president and the Society of Dermatology Nurse Practitioners (SDNP), as one of the founding members, board member, and past president. She is an author of numerous scientific papers in the field of dermatology. Dr Hanna earned her DNP, MSN, and BSN from The University of Kansas. She is a board-certified Dermatology-Certified Nurse Practitioner and Family Nurse Practitioner as well as a fellow of the American Association of Nurse Practitioners and a fellow of the Society of Dermatology Nurse Practitioners.

Mr Clark joined Arcutis in Nov 2018 as the head of program management.  Before Arcutis, Mr Clark was the head of program management at Kite Pharma, where he managed the YESCARTA® Product & Filing Teams, culminating in its BLA being filed 27 months from IND.  He also built out Kite’s PM capabilities – supervising a team of PMs responsible for Kite’s cell therapy portfolio and collaborations.  Prior to Kite, Mr Clark was a global program manager at Amgen where he managed the Kepivance® BLA filing and approval in the US/EU and oversaw a team of PMs responsible for mid-stage Oncology therapeutic programs.  He then transitioned to helping to build out Amgen’s R&D alliance management capability and oversaw a quarter of Amgen’s partnered programs.  His last role was managing the JAPAC team responsible for coordination of Amgen’s strategic (re)entry into Japan, China, and the rest of Asia.  Mr Clark started his career as a community pharmacist in southern Ontario.  He first transitioned into the pharmaceutical industry at Patheon in Mississauga, Ontario as a senior PM accountable for a portfolio of projects for clients including Amgen, Biogen, and Gilead.  Mr Clark earned a bachelor of science degree in pharmacy from the University of Toronto and has an MBA from McMaster University in Hamilton.

Latha Vairavan was promoted to chief financial officer in May 2025 and is responsible for overseeing and managing all financial operations for Arcutis. She has over 20 years of finance and accounting professional experience in the biotech industry.  She joined Arcutis in 2020 and has held roles of increasing responsibility within the organization, beginning as executive director, financial planning and analysis. Most recently, she served as vice president, finance and corporate controller, where she oversaw daily accounting operations, ensured compliance with financial, accounting, and income tax regulations, led all investor relations activities, and managed financial planning and analysis. Prior to Arcutis, Ms Vairavan spent 12 years at Amgen, where she held a variety of roles of increasing responsibility within the finance organization.  She ultimately served as finance director for US value and access.  Ms Vairavan began her career as a financial consultant with KPMG and Arthur Andersen. She holds a bachelors of science in business administration, finance, from the University of Southern California, and is a licensed CPA in California.

Mr Edwards joined Arcutis in September 2023 as chief commercial officer and is responsible for overseeing and managing all commercial operations for Arcutis.  Mr Edwards brings over 25 years of sales, market access, marketing, and general management experience.  Prior to joining Arcutis, he spent almost three years at Incyte as group vice president and business unit head of immunology where he led the successful launch and commercialization of their topical JAK inhibitor for atopic dermatitis.  Prior to that Mr Edwards was at UCB for nearly eight years as the head of US immunology and later head of global immunology operations and strategy, where he was instrumental in leading commercialization of their dermatology, rheumatology, and gastroenterology portfolios.  Prior to that, he held senior roles at AbbVie and TAP Pharmaceuticals.  Mr Edwards holds a BS from East Tennessee State University and an MBA from Embry-Riddle Aeronautical University. He is also a decorated veteran of the US Army.

Dr Snyder joined Arcutis in 2020 leading Patient Safety and Pharmacovigilance. Prior to joining us, Dr Snyder supported Safety Evaluation and Risk Management at Intercept Pharmaceuticals. Prior to this role, Dr. Snyder was at AbbVie where he lead many of the Safety Science activities for medical dermatology products on the market and in clinical development. He also supported the regulatory approval of an additional orphan indication for the treatment of a dermatologic condition in the US and Canada while working in Regulatory Affairs. During his tenure at AbbVie, Dr Snyder supported benefit-risk analyses in the oncology, infectious disease, and general medicine therapeutic areas. Dr Snyder earned his PharmD from Midwestern University’s Chicago College of Pharmacy and subsequently a MS in Biomedical Informatics at University of Chicago.

Mr Tucker is the chief human resources officer at Arcutis, where he leads the growth and development of Arcutis’ team and ensures a world-class corporate culture. He joined the company in July 2020 as executive director of HR.  Prior to Arcutis, Mr Tucker was the senior director of total rewards at Atara Biotherapeutics, where he led the compensation and benefits department. Prior to Atara, Mr Tucker was the senior director and head of human resources at Sienna Biopharmaceuticals, where he established and led the human resources function as the company transitioned from a private to a publicly traded company. Prior to Sienna, Mr Tucker was the associate director of human resources at Kythera. In his role at Kythera he was instrumental in building out the sales force for the company’s launch of Kybella®. He has also held roles in non-profit management where he oversaw all administrative functions, including human resources, information technology, bookkeeping, budgeting, and facilities. Mr Tucker started his career in Amgen’s human resources department, where he held roles of increasing responsibility. He earned a bachelor’s degree in business administration, with an option in human resource management, from California State University, Northridge.

Mr Matsuda joined Arcutis in January 2022 as general counsel and corporate secretary and was appointed chief legal officer in March 2026. He is responsible for all legal and compliance for the company, as well as serving as secretary of the board of directors.

Mr Matsuda previously served as senior vice president, general counsel, chief compliance officer, and corporate secretary at Halozyme Therapeutics, Inc. Prior to Halozyme, he spent 18 years at Amgen in positions of increasing responsibility, most recently as vice president, Law, Global Commercial Operations, where he oversaw strategic commercial legal support to the U.S. Commercial Operations organization, as well as Medical Affairs, Compliance, Global Value, Access & Policy, Global Marketing, and Biosimilars.

Mr Matsuda received a Bachelor of Science in Business Administration with a dual emphasis in corporate finance and international finance from the University of Southern California, and a Juris Doctorate from the University of California, Hastings College of the Law.

Mr Madan brings over 20 years of digital transformation and innovation experience to the Arcutis team. Prior to joining Arcutis, Mr Madan served as the vice president of digital, data/analytics and innovation for consumer healthcare technology at GlaxoSmithKline (GSK), where, in partnership with the chief digital officer, he was responsible for driving significant elements of their digital and tech transformation globally. Before GSK, Mr Madan was with Novartis where he was responsible for managing and delivering global, regional, and localized digital solutions and services across 3 business units and in more than 80 countries. In addition to healthcare, Mr Madan has experience in the consumer goods sector, having spent 14 years at L’Oreal in various roles, including managing the digital tech function for L’Oreal Americas. Mr Madan holds a bachelor’s degree in computer engineering from the New Jersey Institute of Technology and master’s degrees in both business administration and information systems from New York University Stern School of Business.